Trials / Completed
CompletedNCT01290029
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 28 Days – 2190 Days
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cinacalcet | Single, oral dose of 0.25 mg/kg cinacalcet |
Timeline
- Start date
- 2011-01-25
- Primary completion
- 2015-09-23
- Completion
- 2015-09-23
- First posted
- 2011-02-04
- Last updated
- 2020-06-17
- Results posted
- 2016-12-19
Locations
10 sites across 3 countries: United States, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT01290029. Inclusion in this directory is not an endorsement.